DefenCath — Clinical data readout
1H 2027
– DefenCath ® (taurolidine and heparin) TPN indication would add an estimated 5MM annual infusions in the addressable market opportunity, an addressable market of ~$500 - $750MM data in 1H 2027Source filing
CRMD biotech catalysts & pipeline
CORMEDIX INC · Data as of 2026-10-25
Upcoming catalysts
REZZAYO (rezafungin for injection) — PDUFA
in Q1 2027
The sNDA was submitted by Mundipharma, CorMedix's global development partner, and the FDA has granted Priority Review with a Prescription Drug User Fee Act (PDUFA) target action date in Q1 2027.Source filing
REZZAYO (rezafungin for injection) — Regulatory decision
H1 2027
Provided the application is accepted for FDA review, the Company anticipates agency action on the application in H1 2027.Source filing